Novartis taps Roche's neuro and rare disease research lead to run neuroscience research
Even after agreeing to sell off $20 billion in shares back to Roche in November, Novartis got a bit more from its crosstown rival — successfully getting ahold of Roche’s head of research for neuro and rare disease for themselves.
NIBR president Jay Bradner — a well-known name here at Endpoints — announced Bob Baloh’s appointment on Twitter. Baloh will be running NIBR’s neuroscience division.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.